Dori Thomas-Karyat

Company: Synthis LLC

Job title: Chief Executive Officer & Founder


Analyzing How SYN101, An Immune Cell Targeted TGF-β Inhibitor, Selectively Blocks Immune Suppression & Restores Tumor Clearance In Vitro & In Vivo 1:30 pm

Highlighting TGF-β is one of the most immunosuppressive cytokines in cancers Illuminating SYN-101 as a first-in-class, ADC-like molecule that selectively blocks TGF-β mediated immune suppression for cancer patients Accentuating that selective blockade of TGF-β signalling in immune cells restores immune function and drives tumor clearance in vivoRead more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.